- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Epicentrx Inc.
Headquarters: Mountain View, CA, United States
Website: http://www.epicentrx.com
Year Founded: 2002
Status: Private
BioCentury | Nov 8, 2024
Distillery Therapeutics
Sprayable nanorods delivering inflammasome inhibitors for psoriasis
BioCentury | May 23, 2024
Emerging Company Profile
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assembly
BioCentury | Jun 15, 2023
Data Byte
Status of the CD47/SIRPA clinical pipeline
The list of clinical candidates grows as biopharma steps up to overcome hematologic toxicities
BioCentury | Dec 16, 2022
Data Byte
NLRP3 clinical progress
New data from EpicentRx boost confidence in NLRP3 as a cancer target, with a pair of autoimmune programs not far behind
BioCentury | Nov 16, 2021
Data Byte
The oncolytic virus pipeline
At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Jun 6, 2020
Management Tracks
COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more
BioCentury | Dec 6, 2019
Company News
Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more
BioCentury | Nov 13, 2019
Financial News
With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy
BioCentury | Sep 27, 2019
Company News
Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne
Items per page:
1 - 10 of 10